Research programme: bispecific antibody (Novotarg) - Baliopharm AG/University of Tubingen

Drug Profile

Research programme: bispecific antibody (Novotarg) - Baliopharm AG/University of Tubingen

Alternative Names: Bispecific antibody targeting CD20 and CD95 (Novotarg) for autoimmune diseases and cancer - Baliopharm; Novotarg; Protein therapeutic for immune-mediated inflammatory diseases and cancer - Baliopharm

Latest Information Update: 24 May 2016

Price : $50

At a glance

  • Originator University of Tubingen
  • Developer Baliopharm AG
  • Class Bispecific antibodies; Proteins
  • Mechanism of Action CD20 antigen inhibitors; CD95 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inflammation; Lymphoma
  • Research Multiple sclerosis

Most Recent Events

  • 18 May 2016 Baliopharm AG has been acquired by Alvotech
  • 14 Jan 2014 Early research in Multiple sclerosis in Switzerland (Parenteral)
  • 14 Jan 2014 Preclinical trials in Inflammation in Switzerland (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top